The brain drug developer is continuing a trial despite a recommendation it be stopped for futility. Elsewhere, Eli Lilly ...

The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased ...

The meeting, which helps the FDA give guidance to vaccine makers on which flu strains to target, is the second to be ...

The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry ...

While announcing billions of dollars in new U.S. investments, company chief David Ricks called for an extension of 2017 tax ...

The funding comes as Eikon, run by former Merck research chief Roger Perlmutter, has started a Phase 3 trial testing one of ...

The Trump administration’s plans to reduce NIH grant funding could have long-term consequences for the U.S. drug industry, ...

The British drugmaker claimed success in a first-line breast cancer study. Elsewhere, Rezdiffra sales continued to grow and a ...

"Any place that gets cut, it's going to have an impact, because there's not any spare personnel at FDA,” said former agency ...

An industry source said “most, if not all” of the people at CDRH who were recently dismissed are now being asked to return.

Cavazzoni stepped down from her role as head of the FDA’s main drug review office in mid-January. She will succeed Aida ...

Telehealth provider Hims & Hers said it will tell consumers they need to seek “alternative options on the commercial dosing,” ...